JAZZ News and Press, Jazz Pharmaceuticals plc From 10/26/22

Jazz Pharmaceuticals to Report 2022 Third Quarter Financial Results on November 9, 2022 PR Newswire DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 third quarter financial re...

Summary Jazz Pharmaceuticals will pay $50 million upfront for an option to in-license Zymeworks' zanidatamab. Zymeworks carries most of the risk until Jazz opts in. If the deal goes through, Zymeworks would be in a great position to execute its development plan. The deal offer...

Summary After a barely discernible bottoming process, the rally has become obvious. I got a lot of blowback for taking this position but here we are. The market has fallen so much that it has run out of sellers. There are fundamental reasons why the market can rally here. Will...

Shares of Zymeworks (NYSE: ZYME) were soaring 17% higher as of 10:54 a.m. ET on Wednesday. The big jump came after Zymeworks and Jazz Pharmaceuticals (NASDAQ: JAZZ) announced an exclusive licensing deal for zanidatamab. Jazz will pick up development and marketing rights for ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Bukhta Yurii / Shutterstock.com Zymeworks (NYSE: ZYME ) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ ). This agre...

Jazz Pharmaceuticals ( NASDAQ: JAZZ ) signed a licensing agreement for development and commercialization rights to  Zymeworks' ( NYSE: ZYME ) cancer drug zanidatamab in certain regions. Under the agreement, Jazz will pay $50M upfront, after US antitrust...

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody Canada NewsWire Jazz to obtain exclusive development and commercialization rights in key markets including the ...

Stocks have taken us on a wild ride this year. Every time the market looks to be recovering, it drops again. This back and forth could last for several more weeks or months as we're still dealing with various problems, including geopolitical tensions. It may be discouraging, but having a lo...

The growth in legal marijuana in the United States provides a great long-term opportunity for investors. It is expected to go from a market of just over $35 billion in 2022 to a $61 billion market, with a compound annual growth rate (CAGR) of more than 16%, according to cannabis industry an...

Best Cannabis Stocks For October 2022 Are you trying to find the best marijuana stocks to buy before October ? The whole market experienced large drops following the FOMC meeting. Medical marijuana stocks are one component of the cannabis market whose value has maintained steady. In...